JP2022512676A - 大環状インフルエンザエンドヌクレアーゼ阻害剤 - Google Patents
大環状インフルエンザエンドヌクレアーゼ阻害剤 Download PDFInfo
- Publication number
- JP2022512676A JP2022512676A JP2021519876A JP2021519876A JP2022512676A JP 2022512676 A JP2022512676 A JP 2022512676A JP 2021519876 A JP2021519876 A JP 2021519876A JP 2021519876 A JP2021519876 A JP 2021519876A JP 2022512676 A JP2022512676 A JP 2022512676A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- synthesis
- alkyl
- dione
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *C(N(*)C1=O)N(C(c2*****2*C2)c3*2***c3**I)N(C=CC2=O)C1=C2O* Chemical compound *C(N(*)C1=O)N(C(c2*****2*C2)c3*2***c3**I)N(C=CC2=O)C1=C2O* 0.000 description 16
- HSKXBMBUJGAYMO-HSZRJFAPSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SCc3ccc4)c3c4OCCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SCc3ccc4)c3c4OCCCCCN1C2=O HSKXBMBUJGAYMO-HSZRJFAPSA-N 0.000 description 2
- QNDLGTQKURKWSE-UZQCKINESA-N CC(C)c1ccccc1[C@@H](c(c(OC/C=C\CN(C1)C2=O)c3F)ccc3F)N1N(C=CC1=O)C2=C1O Chemical compound CC(C)c1ccccc1[C@@H](c(c(OC/C=C\CN(C1)C2=O)c3F)ccc3F)N1N(C=CC1=O)C2=C1O QNDLGTQKURKWSE-UZQCKINESA-N 0.000 description 1
- QNDLGTQKURKWSE-IYZQMXKPSA-N CC(C)c1ccccc1[C@H](c(ccc(F)c1F)c1OC/C=C\CN(C1)C2=O)N1N(C=CC1=O)C2=C1O Chemical compound CC(C)c1ccccc1[C@H](c(ccc(F)c1F)c1OC/C=C\CN(C1)C2=O)N1N(C=CC1=O)C2=C1O QNDLGTQKURKWSE-IYZQMXKPSA-N 0.000 description 1
- XTCSJMIMXWTMRQ-MBQSCOJDSA-N CC[C@@H](/C=C/COC(C=CCC1F)=C1F)N(CN(Cc1ccccc1C)N(C=CC1=O)C2=C1O)C2=O Chemical compound CC[C@@H](/C=C/COC(C=CCC1F)=C1F)N(CN(Cc1ccccc1C)N(C=CC1=O)C2=C1O)C2=O XTCSJMIMXWTMRQ-MBQSCOJDSA-N 0.000 description 1
- GHDFQZSEKGHNFT-BORZTQPFSA-N CC[C@@H](/C=C/COc(c([C@H](c1ccccc1)N(C1)N(C=CC2=O)C3=C2O)ccc2F)c2F)N1C3=O Chemical compound CC[C@@H](/C=C/COc(c([C@H](c1ccccc1)N(C1)N(C=CC2=O)C3=C2O)ccc2F)c2F)N1C3=O GHDFQZSEKGHNFT-BORZTQPFSA-N 0.000 description 1
- GHDFQZSEKGHNFT-TWRFRYNZSA-N CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O GHDFQZSEKGHNFT-TWRFRYNZSA-N 0.000 description 1
- CGEUWQLSWCOIQL-SRHFXGPLSA-N CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)cccc1Cl)N2C4=O Chemical compound CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)cccc1Cl)N2C4=O CGEUWQLSWCOIQL-SRHFXGPLSA-N 0.000 description 1
- OZFKLQYQUXKDEI-ZTSZUZCLSA-N CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3OCOC(OC)=O)ccc(F)c1F)N2C4=O Chemical compound CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3OCOC(OC)=O)ccc(F)c1F)N2C4=O OZFKLQYQUXKDEI-ZTSZUZCLSA-N 0.000 description 1
- GDVMWTJVEWLGRL-UUHZOMLHSA-N CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2C)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound CC[C@@H](/C=C/COc1c([C@@H](c2ccccc2C)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O GDVMWTJVEWLGRL-UUHZOMLHSA-N 0.000 description 1
- CGEUWQLSWCOIQL-IEVCJYQZSA-N CC[C@@H](/C=C/COc1c([C@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)cccc1Cl)N2C4=O Chemical compound CC[C@@H](/C=C/COc1c([C@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)cccc1Cl)N2C4=O CGEUWQLSWCOIQL-IEVCJYQZSA-N 0.000 description 1
- GHDFQZSEKGHNFT-YTRNJHDKSA-N CC[C@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound CC[C@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O GHDFQZSEKGHNFT-YTRNJHDKSA-N 0.000 description 1
- GHDFQZSEKGHNFT-GIANEKTGSA-N CC[C@H](/C=C/COc1c([C@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound CC[C@H](/C=C/COc1c([C@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O GHDFQZSEKGHNFT-GIANEKTGSA-N 0.000 description 1
- UDWFJEXCPIXVSH-UPVQGACJSA-N COC[C@@H](N(CCCCOc1ccccc1[C@@H]1c2ccccc2)C(C(N2C=CC3=O)=C3O)=O)[N]12S Chemical compound COC[C@@H](N(CCCCOc1ccccc1[C@@H]1c2ccccc2)C(C(N2C=CC3=O)=C3O)=O)[N]12S UDWFJEXCPIXVSH-UPVQGACJSA-N 0.000 description 1
- AFXGKACXRBMHKZ-KQPGBBHGSA-N C[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound C[C@@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O AFXGKACXRBMHKZ-KQPGBBHGSA-N 0.000 description 1
- AFXGKACXRBMHKZ-IZAYXBROSA-N C[C@@H](/C=C/COc1c([C@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound C[C@@H](/C=C/COc1c([C@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O AFXGKACXRBMHKZ-IZAYXBROSA-N 0.000 description 1
- MYXHVJMBDCZXKB-LBPRGKRZSA-N C[C@@H](c(c(OCCCCCN(C1)C2=O)c3F)ccc3F)N1N(C=CC1=O)C2=C1O Chemical compound C[C@@H](c(c(OCCCCCN(C1)C2=O)c3F)ccc3F)N1N(C=CC1=O)C2=C1O MYXHVJMBDCZXKB-LBPRGKRZSA-N 0.000 description 1
- JGTNVZOPQITVEI-DLGQBQFBSA-N C[C@@H](c1cccc(C(F)(F)F)c1OC/C=C\CN(C1)C2=O)N1N(C=CC1=O)C2=C1O Chemical compound C[C@@H](c1cccc(C(F)(F)F)c1OC/C=C\CN(C1)C2=O)N1N(C=CC1=O)C2=C1O JGTNVZOPQITVEI-DLGQBQFBSA-N 0.000 description 1
- AFXGKACXRBMHKZ-CFMZITMMSA-N C[C@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O Chemical compound C[C@H](/C=C/COc1c([C@@H](c2ccccc2)N(C2)N(C=CC3=O)C4=C3O)ccc(F)c1F)N2C4=O AFXGKACXRBMHKZ-CFMZITMMSA-N 0.000 description 1
- WUZVJGJNYGCBNM-ZBADOCLRSA-N C[C@H](c1ccccc1)c(cccc1)c1OCC/C=C\CCN(CNN(C=CC1=O)C2=C1O)C2=O Chemical compound C[C@H](c1ccccc1)c(cccc1)c1OCC/C=C\CCN(CNN(C=CC1=O)C2=C1O)C2=O WUZVJGJNYGCBNM-ZBADOCLRSA-N 0.000 description 1
- FONBMIDRFNFPOB-SNAWJCMRSA-N Cc1ccccc1CN(CN(C/C=C/COc1cccc(F)c1F)C1=O)N(C=CC2=O)C1=C2O Chemical compound Cc1ccccc1CN(CN(C/C=C/COc1cccc(F)c1F)C1=O)N(C=CC2=O)C1=C2O FONBMIDRFNFPOB-SNAWJCMRSA-N 0.000 description 1
- DZUDHQWUHPHVMY-KTBYTZPXSA-N Cc1ccccc1[C@H](c(ccc(F)c1F)c1OC/C=C/CN(C1)C2=O)N1N(C=CC1=O)C2=C1O Chemical compound Cc1ccccc1[C@H](c(ccc(F)c1F)c1OC/C=C/CN(C1)C2=O)N1N(C=CC1=O)C2=C1O DZUDHQWUHPHVMY-KTBYTZPXSA-N 0.000 description 1
- MZRFAMPBSDOZTC-UHFFFAOYSA-N O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)C(c(cccc3)c3SC3)c4c3cccc4OCCCCCN1C2=O Chemical compound O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)C(c(cccc3)c3SC3)c4c3cccc4OCCCCCN1C2=O MZRFAMPBSDOZTC-UHFFFAOYSA-N 0.000 description 1
- OQBZBCAIIVEJTG-DICAFPAZSA-N O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)[C@@H](c3ccccc3)c3ccccc3OC[C@@H](C3)C3(C3)[C@H]3N1C2=O Chemical compound O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)[C@@H](c3ccccc3)c3ccccc3OC[C@@H](C3)C3(C3)[C@H]3N1C2=O OQBZBCAIIVEJTG-DICAFPAZSA-N 0.000 description 1
- CKEPEQANCBZHNG-FOUYOVOOSA-N O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC[C@H](C3)[C@@H]3CN1C2=O Chemical compound O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC[C@H](C3)[C@@H]3CN1C2=O CKEPEQANCBZHNG-FOUYOVOOSA-N 0.000 description 1
- DKEWMWMTQDLDTM-OVWDNRNUSA-N O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3F)c3OC/C=C/CN1C2=O Chemical compound O=C(C=C1)C(OCc2ccccc2)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3F)c3OC/C=C/CN1C2=O DKEWMWMTQDLDTM-OVWDNRNUSA-N 0.000 description 1
- NSCPJHXFFQXVED-TVIPLOHISA-N OC(C(C=C1)=O)=C(C(N(C2)C3(CC3)/C=C/COc3c4Cl)=O)N1N2[C@@H](c1ccccc1)c3ccc4Cl Chemical compound OC(C(C=C1)=O)=C(C(N(C2)C3(CC3)/C=C/COc3c4Cl)=O)N1N2[C@@H](c1ccccc1)c3ccc4Cl NSCPJHXFFQXVED-TVIPLOHISA-N 0.000 description 1
- DWHSGKZXYYWZQP-DHXBXMGCSA-N OC(C(C=C1)=O)=C(C(N(C2)C3(CCC3)/C=C/CO3)=O)N1N2[C@H]1c2ncccc2SCc2c1c3cc(F)c2F Chemical compound OC(C(C=C1)=O)=C(C(N(C2)C3(CCC3)/C=C/CO3)=O)N1N2[C@H]1c2ncccc2SCc2c1c3cc(F)c2F DWHSGKZXYYWZQP-DHXBXMGCSA-N 0.000 description 1
- DWHSGKZXYYWZQP-UXUAMCOBSA-N OC(C(C=C1)=O)=C(C(N(C2)C3(CCC3)/C=C/COc(cc3F)c45)=O)N1N2[C@@H]4c(nccc1)c1SCc5c3F Chemical compound OC(C(C=C1)=O)=C(C(N(C2)C3(CCC3)/C=C/COc(cc3F)c45)=O)N1N2[C@@H]4c(nccc1)c1SCc5c3F DWHSGKZXYYWZQP-UXUAMCOBSA-N 0.000 description 1
- UKDQTMWIDAACQP-OWOJBTEDSA-N OC(C(C=C1)=O)=C(C(N(C2)CC/C=C/CC3)=O)N1N2C(c1ccccc1)c1c3cccc1 Chemical compound OC(C(C=C1)=O)=C(C(N(C2)CC/C=C/CC3)=O)N1N2C(c1ccccc1)c1c3cccc1 UKDQTMWIDAACQP-OWOJBTEDSA-N 0.000 description 1
- RNWSZQBTRSSNRF-HNQUOIGGSA-N OC(C(C=C1)=O)=C(C(N(C2)CCC/C=C/Cc3c4cccc3)=O)N1N2C4c1ccccn1 Chemical compound OC(C(C=C1)=O)=C(C(N(C2)CCC/C=C/Cc3c4cccc3)=O)N1N2C4c1ccccn1 RNWSZQBTRSSNRF-HNQUOIGGSA-N 0.000 description 1
- RNWSZQBTRSSNRF-IWQZZHSRSA-N OC(C(C=C1)=O)=C(C(N(C2)CCC/C=C\Cc3c4cccc3)=O)N1N2C4c1ncccc1 Chemical compound OC(C(C=C1)=O)=C(C(N(C2)CCC/C=C\Cc3c4cccc3)=O)N1N2C4c1ncccc1 RNWSZQBTRSSNRF-IWQZZHSRSA-N 0.000 description 1
- HSKXBMBUJGAYMO-UHFFFAOYSA-N OC(C(C=C1)=O)=C2N1N(C1)C(c(cccc3)c3SC3)c4c3cccc4OCCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)C(c(cccc3)c3SC3)c4c3cccc4OCCCCCN1C2=O HSKXBMBUJGAYMO-UHFFFAOYSA-N 0.000 description 1
- BPGWVQLNXPHEQI-UHFFFAOYSA-N OC(C(C=C1)=O)=C2N1N(C1)C(c3ccccc3)c3ccccc3CCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)C(c3ccccc3)c3ccccc3CCCCCN1C2=O BPGWVQLNXPHEQI-UHFFFAOYSA-N 0.000 description 1
- GWVBHJHJCJICDK-OBPZGGEISA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/[C@@H](C(F)F)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/[C@@H](C(F)F)N1C2=O GWVBHJHJCJICDK-OBPZGGEISA-N 0.000 description 1
- GWVBHJHJCJICDK-JFWNXEFNSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/[C@H](C(F)F)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/[C@H](C(F)F)N1C2=O GWVBHJHJCJICDK-JFWNXEFNSA-N 0.000 description 1
- HSKXBMBUJGAYMO-QHCPKHFHSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OCCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OCCCCCN1C2=O HSKXBMBUJGAYMO-QHCPKHFHSA-N 0.000 description 1
- GCUGXDSCQZWIKH-HOSQHVHZSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OCC[C@@H](C3)[C@@H]3N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c(cccc3)c3SC3)c4c3cccc4OCC[C@@H](C3)[C@@H]3N1C2=O GCUGXDSCQZWIKH-HOSQHVHZSA-N 0.000 description 1
- UPPMHRJZYQQKQY-CRTIWDKESA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3c(C4CC4)cccc3)c3cccc(F)c3OC/C=C/CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3c(C4CC4)cccc3)c3cccc(F)c3OC/C=C/CN1C2=O UPPMHRJZYQQKQY-CRTIWDKESA-N 0.000 description 1
- KLSUIGVHXRLVOZ-JHCPBWHDSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c(cccc3)c3OCC/C=C\CCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c(cccc3)c3OCC/C=C\CCN1C2=O KLSUIGVHXRLVOZ-JHCPBWHDSA-N 0.000 description 1
- COACKJLPCHZWGL-FQEVSTJZSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c3cccc(F)c3OCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c3cccc(F)c3OCCCCN1C2=O COACKJLPCHZWGL-FQEVSTJZSA-N 0.000 description 1
- SJNHARBYICTNAF-NRFANRHFSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c3ccccc3OCCOCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3)c3ccccc3OCCOCCN1C2=O SJNHARBYICTNAF-NRFANRHFSA-N 0.000 description 1
- ULHMKCOMRXZHJX-JYNBPUIZSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3SC3)c4c3cccc4OC/C=C/C3(CC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@@H](c3ccccc3SC3)c4c3cccc4OC/C=C/C3(CC3)N1C2=O ULHMKCOMRXZHJX-JYNBPUIZSA-N 0.000 description 1
- SLVUDCYBXBYIKW-LFTXJPJQSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3S(C3)(=O)=O)c4c3cccc4OC/C=C/CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3S(C3)(=O)=O)c4c3cccc4OC/C=C/CN1C2=O SLVUDCYBXBYIKW-LFTXJPJQSA-N 0.000 description 1
- ULHMKCOMRXZHJX-YTARHJBPSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/C3(CC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/C3(CC3)N1C2=O ULHMKCOMRXZHJX-YTARHJBPSA-N 0.000 description 1
- PYPCKESAMWJVIY-XEMRGCHZSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/C3(CCC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/C3(CCC3)N1C2=O PYPCKESAMWJVIY-XEMRGCHZSA-N 0.000 description 1
- JRMKAQMVVMSJCT-LFTXJPJQSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/CN1C2=O JRMKAQMVVMSJCT-LFTXJPJQSA-N 0.000 description 1
- GWVBHJHJCJICDK-LTETZXIYSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/[C@H](C(F)F)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC/C=C/[C@H](C(F)F)N1C2=O GWVBHJHJCJICDK-LTETZXIYSA-N 0.000 description 1
- IWGDVGXZPQITSB-HKARXFIJSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC[C@H](C3)[C@@H]3CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c(cccc3)c3SC3)c4c3cccc4OC[C@H](C3)[C@@H]3CN1C2=O IWGDVGXZPQITSB-HKARXFIJSA-N 0.000 description 1
- NSCPJHXFFQXVED-LEWSRZTGSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(ccc(Cl)c3Cl)c3OC/C=C/C3(CC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(ccc(Cl)c3Cl)c3OC/C=C/C3(CC3)N1C2=O NSCPJHXFFQXVED-LEWSRZTGSA-N 0.000 description 1
- SJNHARBYICTNAF-OAQYLSRUSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3)c3OCCOCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3)c3OCCOCCN1C2=O SJNHARBYICTNAF-OAQYLSRUSA-N 0.000 description 1
- TWLYQZUCRVMHIK-BBIZLLLXSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3C(F)(F)F)c3OC/C=C\CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c(cccc3C(F)(F)F)c3OC/C=C\CN1C2=O TWLYQZUCRVMHIK-BBIZLLLXSA-N 0.000 description 1
- COACKJLPCHZWGL-HXUWFJFHSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c3cccc(F)c3OCCCCN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c3cccc(F)c3OCCCCN1C2=O COACKJLPCHZWGL-HXUWFJFHSA-N 0.000 description 1
- BNJLOWNQDDRSII-RGPRSXKESA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c3ccccc3OC/C=C/C3(CCC3)N1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3)c3ccccc3OC/C=C/C3(CCC3)N1C2=O BNJLOWNQDDRSII-RGPRSXKESA-N 0.000 description 1
- MCZPJPITOMHTBN-HZQHCPKGSA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3C(F)F)c(ccc(F)c3F)c3OC/C=C\CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3C(F)F)c(ccc(F)c3F)c3OC/C=C\CN1C2=O MCZPJPITOMHTBN-HZQHCPKGSA-N 0.000 description 1
- UPPMHRJZYQQKQY-OSFWOZTASA-N OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3C3CC3)c(cccc3F)c3OC/C=C/CN1C2=O Chemical compound OC(C(C=C1)=O)=C2N1N(C1)[C@H](c3ccccc3C3CC3)c(cccc3F)c3OC/C=C/CN1C2=O UPPMHRJZYQQKQY-OSFWOZTASA-N 0.000 description 1
- YAEVHZGBIZRKBF-OVZCHOQHSA-N OC(C1N(C=C2)N(C3)[C@@H](c4ccccc4SC4)c5c4cccc5OC(C4)CC4CCN3C1=O)C2=O Chemical compound OC(C1N(C=C2)N(C3)[C@@H](c4ccccc4SC4)c5c4cccc5OC(C4)CC4CCN3C1=O)C2=O YAEVHZGBIZRKBF-OVZCHOQHSA-N 0.000 description 1
- YAEVHZGBIZRKBF-BDZTZWKLSA-N OC(C1N(C=C2)N(C3)[C@H](c(cccc4)c4SCc4ccc5)c4c5OC(C4)CC4CCN3C1=O)C2=O Chemical compound OC(C1N(C=C2)N(C3)[C@H](c(cccc4)c4SCc4ccc5)c4c5OC(C4)CC4CCN3C1=O)C2=O YAEVHZGBIZRKBF-BDZTZWKLSA-N 0.000 description 1
- GEYVXKRQBNSHDQ-DEOSSOPVSA-N OC(CC=C1)=C2N1N(C1)[C@@H](c3ccccc3SC3)c4c3cccc4OCCCCCN1C2=O Chemical compound OC(CC=C1)=C2N1N(C1)[C@@H](c3ccccc3SC3)c4c3cccc4OCCCCCN1C2=O GEYVXKRQBNSHDQ-DEOSSOPVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744060P | 2018-10-10 | 2018-10-10 | |
| US62/744,060 | 2018-10-10 | ||
| PCT/IB2019/058591 WO2020075080A1 (en) | 2018-10-10 | 2019-10-09 | Macrocyclic flu endonuclease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512676A true JP2022512676A (ja) | 2022-02-07 |
| JP2022512676A5 JP2022512676A5 (https=) | 2022-10-17 |
Family
ID=68242803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519876A Withdrawn JP2022512676A (ja) | 2018-10-10 | 2019-10-09 | 大環状インフルエンザエンドヌクレアーゼ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11312727B1 (https=) |
| EP (1) | EP3864020A1 (https=) |
| JP (1) | JP2022512676A (https=) |
| KR (1) | KR20210074329A (https=) |
| CN (1) | CN113195502A (https=) |
| AU (1) | AU2019359539A1 (https=) |
| CA (1) | CA3115792A1 (https=) |
| MX (1) | MX2021004182A (https=) |
| TW (1) | TW202035424A (https=) |
| WO (1) | WO2020075080A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| WO2021191872A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Biopharma, Inc. | Heteroaryl-substituted macrocyclic flu endonuclease inhibitors |
| CN113444010B (zh) * | 2020-03-28 | 2023-09-05 | 南京正大天晴制药有限公司 | 一种沙芬酰胺有关物质的制备方法 |
| JP7407976B2 (ja) * | 2020-05-21 | 2024-01-04 | シーセン ファーマシューティカル カンパニー リミテッド | 縮合環誘導体及びその薬学的用途 |
| WO2021249522A1 (zh) * | 2020-06-12 | 2021-12-16 | 上海翰森生物医药科技有限公司 | 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用 |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| EP4384178A4 (en) * | 2021-08-11 | 2025-07-02 | Merck Sharp & Dohme Llc | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLUENZA |
| CN118317964A (zh) * | 2021-11-17 | 2024-07-09 | 辰欣药业股份有限公司 | 一种稠环衍生物的晶型及其制备方法 |
| WO2025015300A2 (en) * | 2023-07-12 | 2025-01-16 | Apac Pharma, Llc | Hepoxilin analogs, methods, uses, and processes for preparation thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8927710B2 (en) * | 2009-06-15 | 2015-01-06 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
| DK2620436T3 (en) * | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| SI3030549T1 (sl) * | 2013-09-12 | 2019-08-30 | Janssen Biopharma, Inc. | Spojine piridazinona in njihove uporabe |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
-
2019
- 2019-10-09 US US17/284,162 patent/US11312727B1/en active Active
- 2019-10-09 MX MX2021004182A patent/MX2021004182A/es unknown
- 2019-10-09 WO PCT/IB2019/058591 patent/WO2020075080A1/en not_active Ceased
- 2019-10-09 EP EP19787467.0A patent/EP3864020A1/en not_active Withdrawn
- 2019-10-09 KR KR1020217013939A patent/KR20210074329A/ko not_active Ceased
- 2019-10-09 CA CA3115792A patent/CA3115792A1/en active Pending
- 2019-10-09 TW TW108136776A patent/TW202035424A/zh unknown
- 2019-10-09 CN CN201980082149.XA patent/CN113195502A/zh active Pending
- 2019-10-09 AU AU2019359539A patent/AU2019359539A1/en not_active Abandoned
- 2019-10-09 JP JP2021519876A patent/JP2022512676A/ja not_active Withdrawn
-
2022
- 2022-03-15 US US17/694,757 patent/US20230002409A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115792A1 (en) | 2020-04-16 |
| US11312727B1 (en) | 2022-04-26 |
| US20230002409A1 (en) | 2023-01-05 |
| EP3864020A1 (en) | 2021-08-18 |
| CN113195502A (zh) | 2021-07-30 |
| AU2019359539A1 (en) | 2021-04-29 |
| MX2021004182A (es) | 2021-09-08 |
| KR20210074329A (ko) | 2021-06-21 |
| WO2020075080A1 (en) | 2020-04-16 |
| TW202035424A (zh) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512676A (ja) | 大環状インフルエンザエンドヌクレアーゼ阻害剤 | |
| JP6916968B1 (ja) | Ｇｌｐ−１受容体アゴニストおよびその使用 | |
| EP2465858B1 (en) | Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative | |
| EP2527007B1 (en) | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | |
| DK2620436T3 (en) | Substituted polycyclic carbamoylpyridone derivative prodrug | |
| KR20170066628A (ko) | Ror-감마의 디히드로피롤로피리딘 억제제 | |
| AU2010240142A1 (en) | Carboxylic acid compound | |
| Dragutan et al. | Enabling access to diverse bioactive molecules through enyne metathesis concepts | |
| WO2017100645A2 (en) | Inhibitors of bacterial rna polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols | |
| EP0861838A2 (en) | Process and intermediates for preparing cryptophycin compounds | |
| CN116888137B (zh) | 羧基取代的糖皮质激素受体激动剂 | |
| FR2916443A1 (fr) | Nouveaux derives analogues de l'herbimycine a, compositions les contenant et utilisation. | |
| EP2274294B1 (en) | 5-demethoxyfumagillol and derivatives thereof | |
| Kiguchi et al. | RADICAL CY CLIZATION IN HETEROCYCLE SYNTHESJS. 7.1 SYNTHESJS OF CHIRAL 2SUBSTIITJTED 5-AMINO-4. PIPEIUDINOLS VIA RADICAL CYCLIZATION | |
| HK40057802A (en) | Macrocyclic flu endonuclease inhibitors | |
| KR101204145B1 (ko) | 비시클로〔３．１．０〕헥산 유도체의 제조 방법, 및 이에 대한 중간체 | |
| CA3210658A1 (en) | Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis | |
| CN114057769A (zh) | 大环哒嗪类化合物及其用途 | |
| Nakagawa et al. | Total synthesis of (−)-eudistomins with an oxathiazepine ring. Part 1. Formation of the oxathiazepine ring system | |
| CN114432308B (zh) | 一种含氮螺环化合物或其药学上可接受的盐在制备抗甲型流感病毒药物中的应用 | |
| JP2013107849A (ja) | 光学活性含フッ素β−アミノ酸誘導体及びその製造法 | |
| CA3256688A1 (en) | BENZOTRIAZOLE COMPOUND | |
| JP2024055860A (ja) | 二環性ピリジン誘導体を含有する医薬 | |
| Nesic | Studies towards the synthesis of bielschowskysin and total synthesis of darobactin A | |
| Haghighi | Asymmetric Allenic Pauson− Khand Reaction to Access Thapsigargin: Influence of a Remote Stereocenter on Stereodifferentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221005 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221005 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20230914 |